The short version
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Doxorubicin Hydrochloride · DOXORUBICIN HYDROCHLORIDE 2 mg/mL · Injection, Suspension, Liposomal · Intravenous · Lupin Pharmaceuticals, Inc.
NDC 70748-0340-01 · 1 VIAL, SINGLE-USE in 1 CARTON / 25 mL in 1 VIAL, SINGLE-USE · ANDA · View full market →
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alembic Pharmaceuticals Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Baxter Healthcare Company | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| BluePoint Laboratories | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Dr. Reddy's Laboratories Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Lupin Pharmaceuticals, Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| GlaxoSmithKline Manufacturing SpA | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
| Baxter Healthcare Corporation | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Doxorubicin Hydrochloride — NDC 70748-0340-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70748034001.
Free to cite with attribution — see how the data is put together.